Honduras vs Jordan: Average cost of multi drug-resistant tuberculosis treatment
Honduras
3,743 constant 2022 US$
in 2024
Jordan
5,124 constant 2022 US$
in 2024
Honduras rank
11th
Jordan rank
8th
Average cost of multi drug-resistant tuberculosis treatment over time
- Honduras
- Jordan
How they compare
Jordan currently reports 5,124 constant 2022 US$ against 3,743 constant 2022 US$ in Honduras, a difference of 1,381 constant 2022 US$.
That makes Jordan's figure about 1.4 times Honduras's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Honduras ahead.
Honduras ranks 11th and Jordan ranks 8th of 92 countries.
Jordan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Honduras | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,711 constant 2022 US$ | 12,250 constant 2022 US$ | 10,539 constant 2022 US$ | Jordan |
| 2020s | 1,891 constant 2022 US$ | 3,905 constant 2022 US$ | 2,014 constant 2022 US$ | Jordan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Honduras or Jordan?
- Jordan, at 5,124 constant 2022 US$ against 3,743 constant 2022 US$ in Honduras as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Honduras and Jordan?
- 1,381 constant 2022 US$, with Jordan ahead.
- How many years of comparable data are there for Honduras and Jordan?
- 8 years are reported by both, from 2017 to 2024.
- How do Honduras and Jordan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Honduras ranks 11th and Jordan ranks 8th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.